Althea Technologies Appoints Dr. Dennis Fenton As Chairman Of Its Scientific Advisory Board
SAN DIEGO, June 19, 2012 /PRNewswire/ — Althea Technologies, a leading provider of development and manufacturing services for biopharmaceutical products, today announced that Dennis Fenton, Ph.D., will chair Althea’s Scientific Advisory Board and be appointed as Board Observer. Dr. Fenton brings 35 years of experience in the biotechnology and pharmaceutical industries to this role. Starting his career at Pfizer Central Research, he subsequently joined Amgen at its inception, where during his 26 year tenure, he helped transform the company from a small biotech to a global leader in the industry. Dr. Fenton’s career is distinguished by his strong track record of scientific expertise and innovation; he also holds 5 US patents in microbiology and has published over 50 papers and abstracts.
“Althea Technologies is very fortunate to be welcoming such an accomplished industry leader to chair its Scientific Advisory Board,” said Dr. Magda Marquet, Founder and Co-Chair of Althea Technologies.
“Dennis Fenton has been a pioneer in translating biologic discoveries to high volume commercial production, and his expanded role supports Althea’s commitment to provide its clients with state of the art clinical and commercial biologic manufacturing solutions,” said Matt Mackowski, Co-Chair of Althea Technologies.
Commenting on his appointment, Dr. Fenton said, “It is an honor to accept the chairman position on Althea’s Scientific Advisory Board. I am excited to contribute my experience in microbiology research within the pharmaceutical industry to Althea’s continued growth as a provider of quality biologics development and manufacturing services.”
Dr. Fenton retired from Amgen in 2008 and has since worked as an independent consultant. Additionally, he has been the member of the boards of Amira, CytomX, Dendreon, Genelux, Genzyme, Kythera, Napo, Xenoport, Rutgers University, the Keck graduate Institute and the Biotechnology Institute. Dr. Fenton received his Ph.D. in Microbiology from Rutgers University.
Althea Technologies’ current Scientific Advisory Board consists of Dr. Steve Kay, Dr. Daniel Wang, and Jeff Yuen.
About Althea Technologies
Althea Technologies is a fully integrated, contract development and manufacturing organization located in San Diego, CA providing clinical and commercial product development services. Althea offers cGMP drug product filling in both vials and syringes, and production of microbial-derived recombinant proteins and plasmid DNA. In conjunction with these manufacturing operations, Althea offers comprehensive development services including: upstream and downstream process development, analytical development, lyophilization cycle, complex formulation, product release and ICH-compliant stability testing. Althea’s formulation technology platform includes Crystalomics®, a proprietary technology that offers a formulation solution for large molecule products that must be delivered at high concentrations or as sustained release formulations. For more information, visit www.altheatech.com.
SOURCE Althea Technologies, Inc.